Amylyx Pharmaceuticals Inc.
Clinical trials sponsored by Amylyx Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including ALS and Alzheimer's disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New ALS drug targets nerve damage in early human trial Results expected Feb 2027 (estimated) May already have reported ↗
-
New drug access for low blood sugar after Weight-Loss surgery
Disease control Expanded accessThis expanded access program offers avexitide to people with post-bariatric hypoglycemia (dangerously low blood sugar) after Roux-en-Y gastric bypass. Eligible patients include those who completed the LUCIDITY trial or other avexitide studies. Participants receive a daily injecti…
Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New ALS drug targets nerve damage in early human trial
Disease control Recruiting nowThis early-stage trial tests a new medicine, AMX0114, in 48 adults with ALS. The drug aims to reduce a protein called calpain-2, which may damage nerves. The main goal is to check safety and how the body handles the drug, not yet to prove it works.
Phase 1 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC